Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Internal Medicine | Pharmacy | Psychiatry | Journal

Back to Journal Articles

Longer Anxiety Therapy Reduces Relapse Rate

Last Updated: December 09, 2010.

 

Stopping venlafaxine XR after 12 months versus six months leads to lower relapse rate

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Patients with generalized anxiety disorder treated with venlafaxine hydrochloride extended release for 12 months have substantially lower relapse rates when they stop the medication than patients who stop the medication after six months, according to a study in the December issue of the Archives of General Psychiatry.

THURSDAY, Dec. 9 (HealthDay News) -- Patients with generalized anxiety disorder (GAD) treated with venlafaxine hydrochloride extended release (XR) for 12 months have substantially lower relapse rates when they stop the medication than patients who stop the medication after six months, according to a study in the December issue of the Archives of General Psychiatry.

Karl Rickels, M.D., of the University of Pennsylvania in Philadelphia, and colleagues randomized 136 GAD patients who had improved on six months of treatment with open-label venlafaxine XR (phase 1) to another six months either on the medication or placebo (phase 2). In a third six-month phase, 59 patients who had been on venlafaxine XR for 12 months were randomized to either continuing the medication or placebo, and all patients on placebo were continued on placebo. The researchers followed the groups for GAD relapse in phases 2 and 3.

The researchers found that the relapse rates in phase 2 were 9.8 percent for patients continuing on venlafaxine XR and 53.7 percent for patients switched to placebo. In contrast, patients who were treated with placebo for a full 12 months had a lower relapse rate (32.4 percent)than those treated with venlafaxine for 6 months before switching to placebo (53.7 percent).

"Treatment of GAD with an antidepressant should be continued for at least 12 months. Preliminary data demonstrate that improved patients who relapse while off their antianxiety medication after at least six months of treatment will again most likely respond to a second course of treatment with the same medication," the authors write.

Wyeth Pharmaceuticals Inc. provided all study medications. Two study authors reported financial ties to medical device and/or pharmaceutical companies, including Wyeth.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2010 HealthDay. All rights reserved.


Previous: Children in Group Care Early See Infection Rates Drop Later Next: Depression Tied to Decreased Gestational Age, Birth Weight

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.